A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
COGNITION THERAPEUTICS INC
CGTX
$28M
Mkt Cap
$0.92
-4.22%
COGNITION THERAPEUTICS INC (CGTX) has a 5-year average return on invested capital (ROIC) of -58.3%. This is below average and may indicate limited pricing power.
COGNITION THERAPEUTICS INC (CGTX) has a market capitalization of $82M. It is classified as a small-cap stock.
COGNITION THERAPEUTICS INC (CGTX) does not currently pay a regular dividend.
COGNITION THERAPEUTICS INC (CGTX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
COGNITION THERAPEUTICS INC (CGTX) generated $-16 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
COGNITION THERAPEUTICS INC (CGTX) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
COGNITION THERAPEUTICS INC (CGTX) reported earnings per share (EPS) of $-0.86 in its most recent fiscal year.
COGNITION THERAPEUTICS INC operates in the Biological Products, (No Diagnostic Substances) industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | -1.8M |
| Net Income | -23M | -26M | -21M | -16M | - |
| EPS | $-0.33 | $-0.86 | $-0.91 | $-0.73 | $-23.76 |
| Free Cash Flow | 0 | -16M | -19M | -3.7M | -3.4M |
| ROIC | -78.0% | -79.7% | -46.8% | -48.4% | - |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.01 | 0.06 | 0.06 | 0.01 | -0.18 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -48M | -51M | -44M | -29M | -17M |
| Operating Margin | 0.0% | - | - | - | 994.1% |
| ROE | -68.5% | -79.7% | -46.8% | 192.2% | - |
| Shares Outstanding | 89M | 30M | 24M | 22M | 1M |
| Metric | |||||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | -1.8M | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | 13M | 19M | 30M | 37M | 37M |
| SG&A | 4.5M | 10M | 13M | 14M | 11M |
| EBIT | -17M | -29M | -44M | -51M | -48M |
| Op. Margin | 994.1% | N/A | N/A | N/A | 0.0% |
| Net Income | N/A | -16M | -21M | -26M | -23M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | N/A | -48.4% | -46.8% | -79.7% | -78.0% |
| ROE | N/A | 192.2% | -46.8% | -79.7% | -68.5% |
| ROA | N/A | -49.0% | -39.1% | -60.3% | -48.5% |
| Cash Flow | |||||
| Op. Cash Flow | -3.4M | -3.6M | -19M | -16M | -25M |
| Free Cash Flow | -3.4M | -3.7M | -19M | -16M | 0 |
| Owner Earnings | -4.0M | -8.9M | -22M | -20M | -27M |
| CapEx | 10K | 27K | 171K | 147K | 0 |
| Maint. CapEx | 98K | 93K | 83K | 96K | 96K |
| Growth CapEx | 0 | 0 | 88K | 51K | 0 |
| D&A | 98K | 93K | 83K | 96K | 96K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 475K | 5.2M | 3.6M | 4.4M | 2.1M |
| Debt Repayment | 4K | 268K | 1.4M | 811K | 811K |
| Balance Sheet | |||||
| Net Debt | 7.2M | -54M | -39M | -28M | -36M |
| Cash & Equiv. | 5.2M | 55M | 42M | 30M | 37M |
| Long-Term Debt | 12M | N/A | N/A | N/A | 353K |
| Debt/Equity | -0.18 | 0.01 | 0.06 | 0.06 | 0.01 |
| Interest Coverage | -9.9 | -32.0 | -1555.4 | -1878.7 | -1878.7 |
| Equity | -68M | 51M | 40M | 24M | 34M |
| Total Assets | 7.1M | 59M | 50M | 35M | 48M |
| Total Liabilities | 75M | 7.9M | 10M | 11M | 14M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -68M | -94M | -115M | -141M | -199M |
| Working Capital | 3.7M | 51M | 40M | 24M | 34M |
| Current Assets | 6.9M | 59M | 48M | 34M | 48M |
| Current Liabilities | 3.3M | 7.9M | 7.8M | 10M | 14M |
| Per Share Data | |||||
| EPS | -23.76 | -0.73 | -0.91 | -0.86 | -0.33 |
| Owner EPS | -7.44 | -0.40 | -0.94 | -0.68 | -0.30 |
| Book Value | -126.55 | 2.31 | 1.71 | 0.82 | 0.39 |
| Cash Flow/Share | -6.37 | -0.16 | -0.79 | -0.53 | -0.26 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.5M | 22.2M | 23.5M | 30.0M | 88.9M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -2.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 3.4 | 1.3 | 2.3 | 2.4 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -2.1% | -36.5% | -28.7% | N/A |
| Market Cap | N/A | 176M | 51M | 56M | 82M |
| Avg. Price | N/A | 9.95 | 2.69 | 1.73 | 0.92 |
| Year-End Price | N/A | 6.00 | 2.18 | 1.88 | 0.92 |
COGNITION THERAPEUTICS INC passes 1 of 9 quality checks, indicating weak fundamentals.
COGNITION THERAPEUTICS INC (CGTX) has a return on equity (ROE) of -79.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for COGNITION THERAPEUTICS INC (CGTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
COGNITION THERAPEUTICS INC (CGTX) has a book value per share of $0.82, based on its most recent annual SEC filing.